JP2024542192A - Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用 - Google Patents

Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用 Download PDF

Info

Publication number
JP2024542192A
JP2024542192A JP2024529415A JP2024529415A JP2024542192A JP 2024542192 A JP2024542192 A JP 2024542192A JP 2024529415 A JP2024529415 A JP 2024529415A JP 2024529415 A JP2024529415 A JP 2024529415A JP 2024542192 A JP2024542192 A JP 2024542192A
Authority
JP
Japan
Prior art keywords
tigit
antibody
bispecific antibody
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542192A5 (https=
JPWO2023088337A5 (https=
Inventor
爽 戴
天 航 ▲ジャイ▼
威 鋒 黄
紹 崗 彭
左 宇 孫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheus Inc
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Publication of JP2024542192A publication Critical patent/JP2024542192A/ja
Publication of JP2024542192A5 publication Critical patent/JP2024542192A5/ja
Publication of JPWO2023088337A5 publication Critical patent/JPWO2023088337A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024529415A 2021-11-17 2022-11-17 Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用 Pending JP2024542192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111359665.8 2021-11-17
CN202111359665.8A CN116135884A (zh) 2021-11-17 2021-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
PCT/CN2022/132422 WO2023088337A1 (zh) 2021-11-17 2022-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途

Publications (3)

Publication Number Publication Date
JP2024542192A true JP2024542192A (ja) 2024-11-13
JP2024542192A5 JP2024542192A5 (https=) 2025-11-25
JPWO2023088337A5 JPWO2023088337A5 (https=) 2025-11-25

Family

ID=86332938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529415A Pending JP2024542192A (ja) 2021-11-17 2022-11-17 Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用

Country Status (8)

Country Link
US (1) US20250019436A1 (https=)
EP (1) EP4435010A4 (https=)
JP (1) JP2024542192A (https=)
KR (1) KR20240103034A (https=)
CN (2) CN116135884A (https=)
AU (1) AU2022389530A1 (https=)
CA (1) CA3238571A1 (https=)
WO (1) WO2023088337A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121712807A (zh) * 2023-08-31 2026-03-20 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途
TW202544031A (zh) * 2024-02-29 2025-11-16 南韓商柳韓洋行股份有限公司 抗tigit/抗pd-l1雙特異性抗體及其用途
CN117924510B (zh) * 2024-03-21 2024-06-04 北京星基贝勤生物科技有限公司 靶向egfr和axl的双特异性抗体及其药物偶联物与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2994858C (en) * 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CN112480253B (zh) * 2019-09-12 2022-09-20 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
CN113461824A (zh) * 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
CN117794952A (zh) * 2021-08-09 2024-03-29 普米斯生物技术(珠海)有限公司 抗tigit抗体及其用途
CN116925222A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途

Also Published As

Publication number Publication date
WO2023088337A1 (zh) 2023-05-25
CA3238571A1 (en) 2023-05-25
CN116135884A (zh) 2023-05-19
KR20240103034A (ko) 2024-07-03
US20250019436A1 (en) 2025-01-16
EP4435010A4 (en) 2025-11-19
CN118251419A (zh) 2024-06-25
EP4435010A1 (en) 2024-09-25
AU2022389530A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US12234286B2 (en) Anti-TIGIT antibodies and their use as therapeutics and diagnostics
US20240352153A1 (en) Pharmaceutical composition and use
US20250019436A1 (en) Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof
JP7780521B2 (ja) 抗ｔｉｇｉｔ抗体、その医薬組成物及び用途
EP4506365A1 (en) Anti-tigit/anti-pvrig bispecific antibody, and pharmaceutical composition and use thereof
EP4506360A1 (en) Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
JP2025524386A (ja) 抗ｃｌｄｎ１８．２抗体を含む二重特異性抗体、並びにその医薬組成物及び使用
JP2024532836A (ja) 抗ＴＩＧＩＴ抗体及びＴＧＦ－βＲを含む融合タンパク質、並びにその医薬組成物及び使用
JP2021523688A (ja) 抗ｃｄ２７抗体およびその使用
JP2026508210A (ja) ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用
TW202305011A (zh) 靶向ｐｄ－１和／或ｏｘ４０的特異性結合蛋白
HK40104756A (zh) 抗tigit抗体及其作为治疗和诊断的用途
HK40031598B (zh) 抗tigit抗体及其作为治疗和诊断的用途
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114